Physician profile
Scott Silliman
NPI 1093783334
$22,031.03
in general payments reported to CMS, 2019-2025
15 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,831 · 2020: $1,258 · 2021: $7,191 · 2022: $1,800 · 2023: $2,074 · 2024: $2,748 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410 · Consulting Fee: $1,305 · Travel and Lodging: $128 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.29 |
| Consulting Fee | $1,305.00 |
| Travel and Lodging | $128.04 |
| Education | $108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $7,347.76 | 2021-2023 | Uplizna |
| Genentech USA, INC. | $5,410.61 | 2019 | |
| Emd Serono, INC. | $2,344.00 | 2019-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $1,786.76 | 2019-2025 | Ultomiris, Soliris |
| Genentech, INC. | $1,238.00 | 2019-2020 | |
| Tg Therapeutics, INC. | $1,044.26 | 2023-2025 | |
| Celgene Corporation | $621.95 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $615.02 | 2022-2025 | |
| Amgen INC. | $522.81 | 2024-2025 | Uplizna |
| Abbvie INC. | $512.24 | 2021-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $314.42 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.42 | 2022 | |
| Lundbeck LLC | $98.66 | 2025 | Vyepti |
| Medtronic, INC. | $23.12 | 2024 | Solitaire X |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Silliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.